A CASE SERIES HIGHLIGHTING THE MEDICAL, PERSONAL AND FINANCIAL IMPACT OF PRESENTING WITH ACUTE PORTOMESENTERIC VEIN THROMBOSIS AT ROYAL FREE HOSPITAL

Sachan Maruthan*, Suj Kim, David Patch. Royal Free Hospital NHS Trust, UK

Background/Aim Acute portomesenteric vein thrombosis (PVT) follows an unpredictable disease course with varying severity and is associated with significant morbidity and mortality. Complications include intestinal ischaemia/infarction, multi-organ failure and death. Treatment objective is restoration of portomesenteric blood flow, with either anticoagulation or thrombolytic therapy. At Royal Free Hospital, systemic thrombolysis is used first line as part of a low dose thrombolysis protocol with multidisciplinary input from hepatology, haematology and interventional radiology. We present a case series of acute PVT and its management, outcome and the financial cost of treatment.

Methods All patients who presented/were transferred to Royal Free Hospital between January 2019 to April 2021 with acute PVT and underwent the low dose thrombolysis protocol were identified from pharmacy dispensing records. Patient demographics, presentation, investigations, management, cost of treatment, complications and outcomes were collected through the electronic patient record and analysed through summary statistics.

Results 41 patients were identified, with an average age of 43 years. 26 patients had a known thrombotic risk factor or were subsequently found to have one. Only 5 patients had previous liver disease. Presenting symptoms included abdominal pain (n=39), nausea/vomiting (n=11), constipation (n=5) and diarrhea (n=5). Systemic thrombolysis was given as initial treatment to 40 patients. All patients had continued symptoms despite initial therapeutic anticoagulation. 13 of these patients subsequently underwent a transjugular intrahepatic portosystemic shunt with subsequent catheter directed thrombolysis for 12 patients. 3 patients required mechanical thrombectomy due to lack of symptom resolution.

Post final treatment, 45% of patients had partial recanalization, 17.5% had complete recanalization whilst 37.5% of patients had no improvement in clot burden. Average duration of thrombolysis was 4.61 days. The cost incurred with the dispensing of alteplase came to an average of over £4657 for each patient.

55% of patients had minor complications from thrombolysis: minor oozing, epistaxis and drop in fibrinogen levels. 2 patients developed major complications: varical bleed and intracranial haemorrhage. 6 patients required surgical intervention due to non-response to medical therapy resulting in small bowel resection. 1 patient died within 24 hours of admission.

Conclusion Using the Royal Free thrombolysis protocol, 62.5% of our patients showed partial or complete recanalization. The study highlights the significant cost associated with just thrombolysis alone. The complexity of the patient population means that the optimal regime/pathway remains to be defined.
TRANSAMINITIS AND IRRITABLE BOWEL SYNDROME (IBS): A COMPREHENSIVE REVIEW

Eyad Gadoue*, Zinab Hassan. University Hospitals of Morecambe Bay NHS Foundation Trust, UK; Stockport Hospital NHS Foundation Trust, Manchester, UK

Abstracts

Transaminitis and Irritable Bowel Syndrome (IBS): A Comprehensive Review

10.1136/gutjnl-2021-BASL.46

Introduction We observed in literature that irritable bowel syndrome (IBS) may be linked with irregular parameters of metabolic system (MS) and liver function. For that reason, we are conducting this systematic review to comprehensively analyze the association of transaminitis (elevated ALT) with IBS.

Methodology This systematic review was designed by following methods described in the Cochrane Handbook for Systematic Reviews of Interventions. Published peer-reviewed journal articles were included. Data was extracted based on study designs Age, gender, author, date of publication or availability online, publication type, participants, gender (M/F) and types of IBS.

Results Our electronic of multiple databases yielded a total of 519 preliminary studies; we then removed duplicate studies and left with 326 studies. After reviewing full text of these articles, a total of 83 studies were eliminated and lastly, three studies were selected for this systematic review for quantitative and qualitative analysis. All the enrolled subjects in included studies were diagnosed with IBS by Rome II and III criteria and among these sub-jects, 50.4% had IBS-D, 13.8% had IBS-C, 30.3% had IBS-M, and 3.5% had IBS-U. The prevalence of elevated alanine aminotransferase (ALT) with other liver enzymes (γ-GT levels and AST) in patients with irritable bowel syndrome whether their BMI were high or not (16.9% vs. 7.7%; p = 0.0015) and γ-GT (24.1% vs. 11.5%; p = 0.037)

Lee et al., 2016. 1 The IBS-D subtype was seen more commonly in patients whose alcohol intake were significantly high however their study data showed no significant change in elevation of ALT. The upper limits normal values for serum liver enzymes were defined as forty-one international per liter in males and thirty-one international unit per liter in females for ALT. No significant relationships were observed between IBS status and elevated γ-GT (OR, 1.647; 95% CI, 0.784–3.461). 1

Conclusion The review study proposes a potential relation between elevated ALT levels, MS, and IBS, and this review might be the first review in IBS patients to observe the association of elevated ALT in IBS population. Although further additional trials with a large sample size will be required confirming these results. Furthermore, for assessing the efficacy of the manipulation of gut microbiota ran–domized controlled trials in a large population of IBS patients are needed to establish a causal-resultant relationship IBS and MS and liver damage.

REFERENCES

THE METABOLIC SWITCH OF HEPATITIS C VIRUS-RELATED HEPATOCELLULAR CARCINOMA AFTER EPHRIN TYPE-A RECEPTOR 2 IS KNOWN DOWN

Zijian Zhang1, Qi Zhou1. Department of General Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China; Digestive Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China; Department of General Surgery, Huayia Hospital of the First Affiliated Hospital of Sun-Yat-sen University, Huizhou, China

10.1136/gutjnl-2021-BASL.47

Purpose Hepatitis C virus (HCV) is a major pathogen of liver diseases, including hepatitis, liver cirrhosis, and hepatocellular carcinoma. Few strategies were applied in the prevention and treatment of Hepatitis C. More and more evidence shows that ephrin receptor A2 (EphA2) is a key factor in the HCV entrance into the liver cells. During our study of metabolic reconstruction of liver cancer cells, we found metabolic progress changed after knocking down the expression of EphA2. That means EphA2 participates not only in the migration, integrin-mediated adhesion, proliferation, and differentiation but also in the metabolic biological processes. We designed an EphA2+metabolic classifier that can distinguish different subtypes of HCV-related HCC which have different characteristics, prognoses, and treatments.

Method Utilizing the data from gene expression omnibus (GEO) and normal liver tissues of GTEx, we focus on the metabolic changes between wild-type HuH7 cells and EphA2-knocked down HuH7 cells. We ran the Gene set enrichment analysis (GSEA) and Gene set variation analysis (GSVA) on the differential expression genes (DEGs) calculated by several packages of R language. And we tried to find the different expression patterns in gene set levels, based on the metabolism-related gene sets. Data from HCV-related HCC in GEO were explored. Bioinformatics methods are used to analyze the genomics, transcriptomics, and clinical data.

Results After utilizing the data from HCV-related HCC of GEO and normal liver tissues of GTEx, 101 LLPs related genes were selected for further research. We ran the GSEA and GSVA, and we found three significantly changed gene sets